Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

Secondary offering of 3 mil. shares is planned at an estimated price of $14.50 per share. The Hayward, California firm, which produces the Cholestech L(D(X point-of-care analyte diagnostic system for multiple blood-detected diseases and disorders, plans to use anticipated net proceeds of approximately $40.4 mil. for expansion of manufacturing capacity in fiscal 1999, R&D expenses, "expansion of sales and marketing capabilities," other capital expenditures and working capital, and SG&A, the SEC filing states. Cholestech recorded sales of $21.7 mil. for the fiscal year ended March 27, 1998 (up 68%); earnings increased to roughly $2 mil. in its first year of profitability. Lead underwriter Prudential Securities and co-managers Vector Securities International and Everen Securities hold an over-allotment option for 450,000 shares, which could bring net proceeds to $46.5 mil

You may also be interested in...

Health And Wellness Trademark Review 18 February, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.

Finance Watch: Revolution Medicines Continues 2020’s Post-IPO Trend

Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts